Helicobacter pylori eradication one-week triple therapy with esomeprazole versus lansoprazole, amoxicillin and clarithromycin: a randomized, open-label, non-inferiority trial.
Phase 3
- Conditions
- Helicobacter pylori infection
- Registration Number
- JPRN-UMIN000007733
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Esomeprazole showed non-inferiority and safety in a 7 day-triple therapy for eradication of H. pylori compared with lansoprazole.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 260
Inclusion Criteria
Not provided
Exclusion Criteria
Past history of allergy for the drugs used in this study. Past history of taking eradication therapy. Past history of gastrectomy. Gastric cancer patients, pregnancy or lactation. Severe renal dysfunction, Blood disease, Infectious Mononucleosis Patients who are disqualified for the study by their physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method on-inferiority trial of the eradication rate of the two regimens, esomeprazole versus lansoprazole based triple therapy
- Secondary Outcome Measures
Name Time Method Comparison between adverse event rates in patients with esomeprazole versus lansoprazole based triple therapy